#USA #Denver #Sobi #Aspaveli #EMPAVELI

Sobi to Present New Data on Aspaveli®/Empaveli®

Sobi®, a notable biopharmaceutical company focused on rare diseases, is set to present new findings related to its product Aspaveli®/Empaveli® (pegcetacoplan) during the upcoming ASN Kidney Week 2026. This annual event will occur from October 21 to 25 in Denver, Colorado, and serves as a significant platform for advancements in nephrology. The company has confirmed that seven abstracts detailing the product's efficacy and safety have been accepted for presentation.

Key Highlights of the Presentation

The presentations at ASN will include two oral discussions and five poster presentations. These sessions will emphasize long-term clinical outcomes, the renal safety profile of pegcetacoplan, and the treatment experience for patients with specific kidney diseases. The findings aim to reinforce Sobi’s dedication to providing robust real-world evidence.

One highlight is the analysis of 76-week outcomes that focus on C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The results indicate that Pegcetacoplan is effective in maintaining a reduction in proteinuria—a key indicator of kidney function—and stabilizing eGFR (estimated glomerular filtration rate).

Oral Presentations

• - First Oral Presentation: This session will examine the pediatric subgroup from the VALIANT study and its extended VALIANT+VALE analysis, providing insights into how young patients respond to this treatment. This presentation is scheduled for October 22, 2026.
• - Second Oral Presentation: Focused on long-term data from patients with C3G and IC-MPGN, this session will report outcomes related to kidney function stabilization, scheduled for October 24, 2026.

Poster Presentations

In addition to the oral presentations, Sobi will showcase five compelling poster presentations:
1. Pilot Study on Preemptive Pegcetacoplan Use: This research involves the impact of early intervention on recurrence rates in kidney transplant recipients, providing valuable insights into post-transplant management.
2. Renal Safety Findings: This includes data on the safety profile of pegcetacoplan drawn from clinical trials and global real-world patient experiences.
3. User Experience with On-Body Injector: Understand how the delivery method of pegcetacoplan improves patient convenience and adherence.
4. Pharmacokinetic and Pharmacodynamic Analyses: These studies will cover the drug's response and its interaction within the body, shedding light on its efficacy.
5. Multi-Country Study on Effectiveness: Real-world data collected from the PRISM-C3 study will demonstrate the treatment's effectiveness in C3G and IC-MPGN patients.

Commitment to Kidney Health

The significance of these presentations cannot be understated. Lydia Abad-Franch, MD, Sobi's Head of R&D and Chief Medical Officer, stated, "Longer-term follow-up is essential to deepen our understanding of treatment outcomes for individuals living with C3G and primary IC-MPGN. The 76-week analyses continue to build a strong evidence base for our therapies.” This underscores Sobi's commitment to enhancing the quality of life for patients suffering from these rare kidney diseases.

Conclusion

Sobi remains at the forefront of developing innovative therapies to support rare disease communities. Their new data on Aspaveli/Empaveli at ASN Kidney Week 2026 is anticipated to contribute significantly to ongoing discussions and research in the nephrology field. With a continuing focus on evidence-based outcomes, Sobi’s initiatives are critical in improving treatment strategies for patients worldwide.